Related Experiment Video
Updated: Apr 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020
Adrian Towse1, Martina Garau1, Penny Mohr2
1Office of Health Economics, 7th Floor, Southside, 105 Victoria Street, Westminster, London, SW1E 6QT, UK.
Aim:
Explore key factors influencing future expectations for the production of evidence of relative effectiveness (RE) for drugs in Europe in 2020; construct three plausible future scenarios for RE evidence generation.
Materials & Methods:
Semi-structured key informant interviews and three rounds of modified Delphi to gather expert perspectives and develop future scenarios.
Results & Conclusion:
Most influential factors were degree of regulator use of postmarketing authorization (postlaunch) efficacy studies and adaptive licensing; degree of pan-European health technology assessment body coordination in reviewing prelaunch evidence and demanding postlaunch studies; the nature of regulator - health technology assessment body interaction. The most likely scenario entailed some change with postlaunch regulatory studies driving the likely nature of RE evidence generated.
Related Concept Videos
Bioequivalence of Drugs: Drugs with Multiple Indications
Dose-Response Relationship: Potency and Efficacy
Bioequivalence: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Combined Effects of Drugs: Synergism
Such synergistic combinations...

